FNDC9

Across TCGA pan-cancer cohorts, FNDC9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FNDC9 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FNDC9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FNDC9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, COAD, and SKCM are the cancer types where FNDC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	36	view →
COAD	DFS	Median	All	0.443	0.783	.010	12	view →
SKCM	DFS	Median	All	0.450	0.743	.005	4	view →
UCEC	DFS	Median	All	1.000	0.631	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FNDC9–LIHC (OS)

Open the LIHC breakdown →